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We evaluated the clinical significance of prognostic factors including the Interna-
tional Staging System (ISS) and modified European Group for Blood and Marrow
Transplantation response criteria in 1650 Japanese patients with multiple myeloma
(MM) who underwent upfront single autologous stem cell transplantation (ASCT).
We categorized patients into two treatment cohorts: pre-novel agent era (1995–
2006) and novel agent era (2008–2011). The combined percentage of pre-ASCT
complete response and very good partial response cases (463 of 988, 47%) signifi-
cantly increased during the novel agent era compared with the pre-novel agent
era (164 of 527, 31%; P < 0.0001). The 2-year overall survival (OS) rate of 87%
during the novel agent era was a significant improvement relative to that of 82%
during the pre-novel agent era (P = 0.019). Although significant differences in OS
were found among ISS stages during the pre-novel agent era, no significant differ-
ence was observed between ISS I and II (P = 0.107) during the novel agent era. The
factors independently associated with a superior OS were female gender
(P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre-ASCT
response at least partial response (P < 0.001) and ASCT during the novel agent era
(P = 0.017). These results indicate that the response rate and OS were significantly
improved, and the ISS could not clearly stratify the prognoses of Japanese patients
with MM who underwent upfront single ASCT during the novel agent era.
T he prognosis of patients with multiple myeloma (MM)has improved since the introduction of novel treatment
agents such as bortezomib, thalidomide and lenalidomide.
Bortezomib is classified as a proteasome inhibitor and thalido-
mide ⁄ lenalidomide as immunomodulator drugs. During the
pre-novel agent era, an international collaborative project
developed the International Staging System (ISS) based on
serum albumin and b2-microglobulin levels.(1) This system has
been widely used in both young and elderly patients with MM
treated with either conventional chemotherapy or autologous
stem cell transplantation (ASCT) after high-dose melphalan
conditioning during the novel agent era. However, the validity
of the ISS for prognostic predictions has not been verified in
Asian patients with MM. We analyzed the prognostic factors
of a large cohort of newly diagnosed Japanese patients with
MM who underwent upfront single ASCT after high-dose
melphalan (200 mg ⁄m2; Mel 200) treatment during both the
pre-novel and novel agent eras.
Materials and Methods
Data source and patients. For this retrospective observational
study, data were collected and analyzed using the Transplant
Registry Unified Management Program (TRUMP) of the Japan
Society for Hematopoietic Cell Transplantation (JSHCT). Patient
consent is not required for JSHCT TRUMP registration because
the registry data comprise anonymized clinical information.
This study was approved by the data management committees
of JSHCT and the institutional review boards of the Kanazawa
University Graduate School of Medical Science, Japan.
Because bortezomib, thalidomide and lenalidomide were
released for treatment of relapse ⁄ refractory MM in Japan in
December 2006, February 2009 and July 2010, respectively,
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we categorized the patients into two treatment cohorts: pre-
novel (1995–2006) and novel agent eras (2008–2011). The
study participants included 1650 Japanese patients (936 men
and 714 women) with a median age of 58 years (range:
18–73 years) who underwent upfront single ASCT after Mel
200 treatment for newly diagnosed symptomatic MM; all
patients underwent an ASCT in Japan between October 1995
and December 2011. Because bortezomib was released for the
treatment of relapse ⁄ refractory MM on 1 December 2006 and
approved for the treatment of previously untreated MM on 16
September 2011, most patients who underwent an ASCT in
2007–2011 were first treated with conventional chemothera-
pies, such as VAD (infusional vincristine, doxorubicin and
pulsed dexamethasone) or high-dose dexamethasone, but when
patients did not achieve a sufficient response, they were then
treated with novel agents before ASCT. Patients who under-
went an ASCT in 2007 were excluded, because bortezomib
was released in December 2006 and a relatively large number
of these patients were assumed to have received induction che-
motherapy without the use of novel agents. The overall
survival (OS) curve of patients who underwent an ASCT in
2007 was located between that in 1995–2006 and that in
2008–2011 (data not shown). All patients were diagnosed with
MM based on institutional assessment. When ASCT was per-
formed between January 2004 and December 2011, patient
responses to therapy were assessed based on the criteria of the
European Group for Blood and Marrow Transplantation,(2)
which was modified to include very good partial response
(VGPR) and stable disease (SD), and categorized as either a
complete response (CR), VGPR, partial response (PR), SD or
Table 1. Patient characteristics
ASCT during pre-novel agent era (until 31 December
2006) (n = 654)
ASCT during novel agent era
(after 1 January 2008) (n = 996)
P-value
October 1995–December
2003 (n = 117)
January 2004–December
2006 (n = 537)
January 2008–December 2011
Median age, years (range) at ASCT 54 (23–68) 57 (22–70) 59 (18–73) <0.001
Age ≤65 at ASCT, n (%) 113 (96.6) 517 (96.3) 937 (94.1) 0.0497
Male, n (%) 62 (53.0) 297 (55.3) 577 (58.0) 0.223
Performance status at ASCT, n (%)
0 or 1 100 (85.5) 475 (88.5) 906 (91.0) 0.789
>1 7 (6.0) 51 (9.5) 87 (8.7)
Unknown 10 (8.5) 11 (2.0) 3 (0.3)
ISS stage at diagnosis, n (%)
I 21 (17.9) 148 (27.6) 342 (34.3) 0.992
II 21 (17.9) 167 (31.1) 376 (37.8)
III 19 (16.2) 90 (16.8) 216 (21.7)
Unknown 56 (47.9) 132 (24.6) 62 (6.2)
Myeloma type, n (%)
Light-chain only 23 (19.7) 81 (15.1) 182 (18.3) 0.194
IgA 21 (17.9) 109 (20.3) 198 (19.9)
IgG 65 (55.6) 316 (58.8) 553 (55.5)
IgD 5 (4.3) 16 (3.0) 28 (2.8)
IgM 0 1 (0.2) 2 (0.2)
Non-secreting 0 9 (1.7) 31 (3.1)
Unknown 3 (2.6) 5 (0.9) 2 (0.2)
Planned post-ASCT therapy, n (%)
Thalidomide 0 1 (0.2) 28 (2.8) <0.001
Bortezomib 0 0 24 (2.4) <0.001
Lenalidomide 0 0 31 (3.1) <0.001
Pre-ASCT response, n (%) CR 45 (8.4) CR 123 (12.3)
nCR 18 (15.4) VGPR 119 (22.2) VGPR 340 (34.1)
PR 64 (54.7) PR 285 (53.1) PR 434 (43.6)
SD 11 (9.4) SD 62 (11.5) SD 76 (7.6)
PD 4 (3.4) PD 16 (3.0) PD 15 (1.5)
NA 20 (17.1) NA 10 (1.9) NA 8 (0.8)
CR + VGPR NA 164 (31.1) 463 (46.9) <0.001
Non-CR + Non-VGPR NA 363 (68.9) 525 (53.1)
Post-ASCT response, n (%) NA CR 45 (15.9) 182 (26.4) <0.001
Non-CR 238 (84.1) 508 (73.6)
NA 254 306
P-value, comparison between pre-novel and novel agent eras. Because the response of patients (n = 4) who underwent ASCT between October
1995 and December 1996 was based on institutional assessment, we excluded them from the pre-ASCT response assessment. ASCT, autologous
stem cell transplantation; CR, complete response; ISS, International Staging System; NA, not assessed; nCR, near complete response; PD, progres-
sive disease; PR, partial response; SD, stable disease; VGPR, very good partial response or better.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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progressive disease (PD). Because we could not exclude the
possibility that immunofixation electrophoresis tests were not
performed in some VGPR cases, VGPR or better is indicated
in this study. VGPR was defined by a ≥90% reduction in M-
component levels in the serum by electrophoresis (EP) in addi-
tion to PR criteria, and SD was defined as minor response
(MR) plus no change (NC). In contrast, when ASCT was per-
formed between January 1997 and December 2003, the
responses to therapy were assessed as follows: near CR
required the absence of detectable M-component levels in the
serum and urine by EP and plasmacytomas, which was main-
tained for a minimum of 4 weeks without the emergence of
new lesions, together with ≤5% plasma cells in the bone mar-
row on the recovery of peripheral white blood cell counts,
platelet counts, and Hb to ≥2.5 9 109 ⁄L, ≥100 9 109 ⁄L and
≥10 g ⁄ dL, respectively. If chemotherapy and ⁄or interferon
treatment had adverse effects on blood recovery, the aforemen-
tioned peripheral blood recovery was not required. PR was
defined by a ≥50% reduction in M-component levels in the
serum and urine by EP and a ≥50% reduction in the size of
plasmacytomas (=long diameter 9 short diameter), if two
dimensions were measurable, or a ≥30% reduction, if only one
dimension was measurable, which was maintained for a mini-
mum of 4 weeks without the emergence of new lesions. MR
was defined as follows: (i) a 25–50% reduction in M-compo-
nent levels in the serum and urine by EP, or a ≥50% reduction
in M-component levels in the serum and urine by EP for
<4-week duration; (ii) a 25–50% decrease in plasmacytoma
size (=long diameter 9 short diameter), if two dimensions
were measurable, or a ≥50% decrease in plasmacytoma size
for <4-week duration (a 15–30% decrease, if only one dimen-
sion was measurable, or ≥30% decrease in plasmacytomas size
for <4-week duration); and (iii) no emergence of new lesions
for a minimum of 4 weeks. PD was defined as an increase in
M-component levels and ⁄or plasmacytomas or the emergence
of new lesions. The remaining patients without new lesions for
a minimum of 4 weeks were considered as NC, and SD was
defined as MR plus NC. Because the response of patients
(n = 4) who underwent ASCT between October 1995 and
December 1996 was based on an institutional assessment, we
excluded them from the pre-ASCT response assessment.
Statistical analysis. Continuous variables were analyzed using
the Student t test, and categorical variables were analyzed
using Fisher’s exact test. The OS was calculated from the time
of diagnosis or ASCT until the date of death, by any cause, or
the date of last contact. Patients who could not be followed up
were censored at the date of last contact. Survival curves were
plotted according to the Kaplan–Meier method, and the log-
rank test was used for comparisons among the groups. The
Cox proportional hazard model was used to calculate the haz-
ard ratios (HR) for each variable along with the 95% confi-
dence interval (CI). A multivariate analysis was conducted by
(a) (b) (c)
Fig. 1. Overall survival (OS) from the time of autologous stem cell transplantation (ASCT) of patients who underwent ASCT during the pre-
novel and novel agent eras (a); males (b) and females (c).




Age ≤65 at ASCT 84.5 (82.3–86.4) 0.603
Age >65 at ASCT 83.2 (70.5–90.8)
Male 83.9 (81.0–86.3) 0.014
Female 85.2 (81.9–87.9)
Performance status at ASCT
0 or 1 85.7 (83.6–87.7) <0.001
>1 74.0 (65.0–81.1)
ISS stage at diagnosis










CR 90.6 (84.8–94.3) 0.001
Non-CR 85.4 (82.3–88.1)
ASCT during pre-novel agent era 82.0 (78.7–84.8) 0.019
ASCT during novel agent era 86.8 (84.1–89.2)
Pre-ASCT and post-ASCT responses were analyzed using the data of
pre-novel (January 2004–December 2006) and novel agent eras (Janu-
ary 2008–December 2011). The overall survival was calculated from
the time of ASCT. ASCT, autologous stem cell transplantation; CR,
complete response; ISS, International Staging System; PD, progressive
disease; PR, partial response; SD, stable disease; VGPR, very good par-
tial response or better.
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entering all variables that were associated with survival at a
significance level of P < 0.05 into a Cox proportional hazard
model. All statistical analyses were performed using the EZR
software package (Saitama Medical Center ⁄ Jichi Medical Uni-
versity, Saitama, Japan)(3) along with a graphical user interface
for the R software package (version 2.13.0; The R Foundation
for Statistical Computing). A multivariate analysis was per-
formed using the EZR software package (Saitama Medical
Center ⁄ Jichi Medical University)(3) and SAS version 9.2 soft-
ware (SAS Institute, Cary, NC, USA). P-values of <0.05 were
considered significant in all analyses.
Results
The characteristics of patients before and after the approval of
novel agents are shown in Table 1. There were no significant
differences between the groups with regard to gender, perfor-
mance status (PS) at ASCT, ISS categorization at diagnosis
and myeloma type, except for age at ASCT, and planned post-
ASCT therapy.
During the pre-novel agent era, 654 patients in Japan (359
men and 295 women) with a median age of 56 years (range:
22–70 years) underwent upfront single ASCT after Mel 200
treatment between October 1995 and December 2006. The
median follow-up duration was 4.2 years with a 2-year OS rate
of 82.0% (95% CI, 78.7–84.8), a 4-year OS rate of 64.7%
(95% CI, 60.6–68.4) and the median survival was 6.3 years.
During the novel agent era, 996 patients in Japan (577 men and
419 women) with a median age of 59 years (range: 18–
73 years) underwent single ASCT after Mel 200 treatment
between January 2008 and December 2011. The median
follow-up duration was 1.6 years with a 2-year OS rate of
(a) (b)
(c) (d)
Fig. 3. Pre-autologous stem cell transplantation
(ASCT) responses of patients who underwent ASCT
during the pre-novel agent ([a] complete response
[CR], 45 cases; very good partial response [VGPR],
119 cases; partial response [PR], 285 cases; stable
disease [SD], 62 cases; progressive disease [PD], 16
cases) and novel agent eras ([b] CR, 123 cases;
VGPR, 340 cases; PR, 434 cases; SD, 76 cases; PD, 15
cases). Post-ASCT responses of patients who
underwent ASCT during the pre-novel agent ([c]
CR, 45 cases; non-CR, 238 cases) and novel agent
eras ([d] CR 182 cases; non-CR, 508 cases). Overall
survival (OS) was calculated from the time of ASCT.
These responses were analyzed using the data of
pre-novel (January 2004–December 2006) and novel
agent eras (January 2008–December 2011) based on
the same response criteria.
(a) (b)
Fig. 2. The International Staging System (ISS)
scores for patients who underwent autologous
stem cell transplantation (ASCT) during the pre-
novel (a) and novel agent eras (b). The overall
survival (OS) was calculated from the time of
diagnosis.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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86.9% (95% CI, 84.1–89.2). The OS during the novel agent era
was significantly improved in comparison to the OS during the
pre-novel agent era (P = 0.019; Fig. 1a). The factors associated
with a superior OS were female gender (P = 0.014), a good PS
(P < 0.001) and a low ISS score (P < 0.001; Table 2).
Although the OS of female patients with MM significantly
improved during the novel agent era (P = 0.002), the OS of
male patients with MM did not (P = 0.592; Figs 1b,c,5). The
median survival rates from the time of diagnosis for the ISS I
(n = 168), II (n = 188) and III (n = 109) groups during the
pre-novel agent era were 12.9, 7.2 and 5.4 years, respectively
(Fig. 2a). The OS was significantly different when the ISS I
group was compared with the ISS II (P = 0.008) and III
(P < 0.001) groups and between the ISS II and III groups
(P = 0.027). The 2-year OS rates from the time of diagnosis
for the ISS I (n = 342), II (n = 376) and III (n = 216) groups
during the novel agent era were 96%, 93% and 90%, respec-
tively (Fig. 2b). In the ISS I group, the OS was significantly
prolonged compared with the ISS III group (P < 0.001), but no
significant differences were found between the ISS I and II
groups (P = 0.107; Fig. 2b). The period from diagnosis to
ASCT in the pre-novel agent era was 64–6079 days (median
213 days) and that in the novel agent era was 18–7201 days
(median 218 days), and the difference between these groups
was not significant (P = 0.82 by unpaired t-test; P = 0.60 by
Mann–Whitney U-test). The pre-ASCT responses during the
pre-novel agent era (January 2004–December 2006) were as
follows: CR, 45 cases (8%); VGPR, 119 cases (22%); PR, 285
cases (53%); SD, 62 cases (12%); PD, 16 cases (3%); and no
data, 10 cases (2%; Table 1). The 2-year OS rates for the CR,
VGPR, PR, SD and PD groups were 82%, 82%, 85%, 73% and
65%, respectively. The median survival durations for the CR,
VGPR, PR, SD and PD groups were not reached, 6.6, 6.4, 4.8,
and 3.7 years, respectively (Fig. 3a). There were no significant
differences in the OS between the CR group and the other
response groups. The pre-ASCT responses during the novel
agent era were as follows: CR, 123 cases (12%); VGPR, 340
cases (34%); PR, 434 cases (44%); SD, 76 cases (8%); PD, 15
cases (2%); and no data, eight cases (1%; Table 1). The 2-year
OS rates for the CR, VGPR, PR, SD, and PD groups were
87%, 91%, 86%, 84% and 36%, respectively. There were no
significant differences in the OS between the CR group and the
other response groups, except between CR and PD (P < 0.001;
Fig. 3b). The percentage of pre-ASCT CR + VGPR cases (463
of 988, 47%) during the novel agent era significantly increased
in comparison with that during the pre-novel agent era (164 of
527, 31%; P < 0.001; Table 1), and there was a significant dif-
ference in the OS between the pre-ASCT CR + VGPR and PR
groups during the novel agent era (P = 0.003; Fig. 3b). The
post-ASCT CR rate during the novel agent era (182 of 690,
26%) also significantly increased compared with the pre-novel
agent era rate (45 of 283, 16%; P < 0.001; Table 1). There
were significant differences in the OS between the post-ASCT
CR and non-CR groups during both the pre-novel and novel
agent eras (Fig. 3c,d).
In a multivariate analysis, we analyzed the baseline factors
that were significant in a univariate analysis; the post-ASCT
response was excluded based on data unavailability for a large
number of cases. The factors that were independently associ-
ated with superior OS were female gender (P = 0.002), PS of
0 or 1 (P = 0.024), ISS I versus II (P = 0.046) and III
(P < 0.001), a pre-ASCT response better than or equal to PR
(P < 0.001), and ASCT during the novel agent era
(P = 0.017; Table 3). We classified patients into five catego-
ries on the basis of the number of prognostic factors (male
gender, PS of 2, 3 or 4, ISS II or III, a pre-ASCT response
less than PR, and ASCT during the pre-novel agent era). The
numbers of patients with 0, 1, 2, 3, 4 and 5 prognostic factors
were 251, 593, 394, 126, 17 and 1, respectively. We con-
ducted Kaplan–Meier analysis according to the number of
prognostic factors and revealed a clear OS stratification
(Fig. 4). Only one patient displayed all five prognostic factors,
and his OS was not shown. The patients who were included
in this analysis underwent an ASCT during pre-novel (October
1995–December 2006) and novel agent (January 2008–Decem-
ber 2011) eras.
To further clarify the effects of novel agents across the vari-
ous risk groups, we analyzed the differences in the OS of the
groups before and during the novel agent era with respect to
well-known prognostic factors (Fig. 5). In a comparison of the
pre-novel and novel agent eras, the following factors were
associated with a better OS: age ≤65 years (P = 0.024) at
Table 3. Univariate and multivariate analysis for survival
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age >65 vs ≤65 at ASCT 1.130 (0.713–1.791) 0.603 NA
Male vs female 1.275 (1.049–1.550) 0.015 1.456 (1.155–1.837) 0.002
PS >1 vs 0 or 1 at ASCT 1.321 (1.142–1.528) <0.001 1.477 (1.053–2.071) 0.024
ISS stage at diagnosis
I 1.000 – 1.000 –
II 1.413 (1.079–1.852) 0.012 1.322 (1.005–1.739) 0.046
III 1.408 (1.220–1.624) <0.001 1.840 (1.376–2.461) <0.001
Pre-ASCT response
CR ⁄ nCR ⁄ VGPR ⁄ PR vs SD ⁄ PD 1.206 (1.110–1.311) <0.001 1.680 (1.240–2.277) <0.001
Post-ASCT response
Non-CR vs CR 1.939 (1.284–2.930) 0.002 NA
ASCT during pre-novel agent era vs during novel agent era 1.310 (1.044–1.643) 0.020 1.366 (1.060–1.761) 0.017
The overall survival was calculated from the time of ASCT. The patients who were included in this analysis underwent an ASCT during pre-novel
(October 1995–December 2006) and novel agent (January 2008–December 2011) eras. ASCT, autologous stem cell transplantation; CR, complete
response; ISS, International Staging System; NA, not applicable; nCR, near complete response; PD, progressive disease; PR, partial response; PS,
performance status; SD, stable disease; VGPR, very good partial response or better.
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ASCT, female gender (P = 0.002), PS of 0 or 1 (P = 0.044) at
ASCT and ISS II (P = 0.046) at diagnosis.
Discussion
Novel agents have markedly changed therapies for MM. Tha-
lidomide, lenalidomide and bortezomib were approved in the
USA in 2006, 2006 and 2003, respectively, and were approved
in many European Union member nations in 2008, 2007 and
2004, respectively. According to clinical studies performed in
Europe and the USA in which novel agents had been intro-
duced earlier than in Asian countries, significant improvements
in responses and survival were observed in patients with MM
who had been treated with novel agents.(4–6) However, few
reports have described the outcomes of patients with MM who
have been treated with novel agents in Asian countries. Our
first aim was to provide the initial analysis of prognostic fac-
tors in a large cohort of newly diagnosed Japanese patients
with MM who underwent single upfront ASCT during the
novel agent era. OS significantly improved during the novel
agent era and significant improvements in the 2-year OS were
confirmed in patients with MM who were younger (≤65 years
at ASCT; 82% vs 87%; P = 0.024), female (80% vs 90%;
P = 0.002) and with a good PS (0 or 1 at ASCT; 83% vs
88%; P = 0.044; Fig. 5). These findings are consistent with
those of previous reports.(6) Kastritis et al. demonstrate that
the median OS in patients who began treatment after the intro-
duction of novel agents increased by 12 months (48 vs
36 months; P < 0.001). This improvement was more pro-
nounced in younger (≤70 years; 39 vs 74 months; P < 0.001)
and female (36 vs 59 months; P = 0.001) patients but was less
evident in older (>70 years; 26 vs 33 months; P = 0.27) and
male patients (37.5 vs 40.5 months; P = 0.062).(6) Kumar
et al.(4) report that in a larger cohort of 2981 newly diagnosed
patients with myeloma, those who had been diagnosed in the
previous decade experienced a 50% improvement in the OS
(44.8 vs 29.9 months; P < 0.001). Furthermore, Costa et al.(7)
also demonstrate by multivariate analysis using Center for
International Blood and Marrow Transplant Research (CI-
BMTR) data that ASCT in the 2000–2004 cohort (n = 6408;
HR = 0.77) or in the 2005–2010 cohort (n = 11 644;
HR = 0.68) were associated with lower risk of death compared
with the 1995–1999 (n = 2226) cohort. Although we do not
know the reason for a superior OS in female MM patients,
Kristinsson et al.(8) and Kumar et al.(4) also show enhanced
survival in female patients with MM using a total of 14 381
and 2981 patients, respectively. Landgren et al.(9) report that
estrogen medication has been found to reduce the risk of
developing MM among females, potentially due to the block-
ing effects on interleukin-6-mediated MM cell growth.(10)
Our second aim was to validate the ISS in Japanese patients
with MM during the pre-novel and novel agent eras. Although
our results demonstrate that the ISS could be used to stratify
the OS of patients who underwent ASCT during the pre-novel
agent era, we could not clearly stratify the prognosis of Japa-
nese patients with MM in the ISS I and II groups who under-
went upfront single ASCT during the novel agent era. In the
pre-novel agent era, Nagura et al.(11) report that the ISS could
stratify Japanese patients with MM who were treated with che-
motherapy and ASCT. Kim et al.(12) also report that the ISS
could predict the prognosis of Korean patients with MM who
underwent ASCT as a first-line therapy during the pre-novel
agent era. Furthermore, Kastritis et al.(6) report that the ISS
was applicable in patients during the novel agent era. In con-
trast, Hari et al.(13) demonstrate using the CIBMTR data that
the ISS III stage (n = 449) was associated with a higher risk
Fig. 4. Overall survival (OS) from the time of autologous stem cell
transplantation (ASCT) according to the number of prognostic factors;
male gender, performance status (PS) of 2, 3 or 4, the International
Staging System (ISS) II or III, a pre-autologous stem cell transplanta-
tion (ASCT) response less than the partial response (PR), and ASCT dur-
ing the pre-novel agent era. Only one patient displayed all five
prognostic factors and his OS was not shown. The patients who were
included in this analysis underwent an ASCT during pre-novel (Octo-
ber 1995–December 2006) and novel agent (January 2008–December
2011) eras.
Fig. 5. Impact of autologous stem cell
transplantation (ASCT) during the novel agent era
on the overall survival (OS) from the time of ASCT
in each stratified category. Effects of ASCT during
the novel agent era are shown as forest plots.
Circles on lines indicate hazard ratios compared
with “ASCT during the pre-novel agent era,” and
horizontal lines represent the corresponding 95%
confidence interval (CI). Pre-ASCT responses were
analyzed using the data of pre-novel (January
2004–December 2006) and novel agent eras
(January 2008–December 2011) based on the same
response criteria. ISS, International Staging System;
PS, performance status.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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of mortality compared with the ISS II stage (n = 230;
P = 0.007) but not the ISS II stage compared with the ISS I
stage (n = 50; relative risk = 1.10, P = 0.482) in patients who
received upfront ASCT for MM in the pre-novel agent era.
Tan et al.(14) recently compared the OS of 221 patients with
MM in Singapore who had been diagnosed from 2006 to 2009
(era 2), when an upfront bortezomib combination was
approved for high-risk MM, with the OS of 262 patients who
had been diagnosed from 2000 to 2005 (era 1), when bortezo-
mib could only be administered upon relapse. The median OS
was 4.2 years and was not reached in eras 1 and 2 (P = 0.03).
The ISS retained its prognostic significance in era 1
(P < 0.001) but not in era 2 (P = 0.07), a finding that was
consistent with our results. Iriuchishima et al.(15) also report
the lack of a significant difference between the ISS stages
among Japanese patients with MM in the novel agent era. The
patients in the previous reports who received initial treatment
other than single ASCT following high-dose melphalan
(200 mg ⁄m2; Mel 200), such as tandem ASCT, melphalan
<200 mg ⁄m2 or conventional chemotherapy, were included;
therefore, it is of particular concern that this analysis was
based on highly selected patients who underwent single ASCT
following Mel 200. In the near future, novel prognosis models
that include chromosomal and genetic data will be used to
accurately predict the OS of patients with MM in place of the
ISS.
Given the lack of available pre-ASCT induction regimen
information in our database, we could not extract the data for
patients with MM who actually received novel agents during
the novel agent era for our analysis. The Kansai Myeloma
Forum, a Japanese MM study group, reported that 95 cases
received high-dose melphalan therapy with stem cell support
from 2006 to 2013 and 83 of the 95 (87%) cases received at
least one of the novel agents during their clinical courses.(16)
According to that report, in clinical practice, from 2006,
approximately 90% of all transplant-eligible Japanese patients
with MM received therapy with the novel agents. Therefore, it
is reasonable to assume that many of the patients who under-
went ASCT between 2008 and 2011 were treated with novel
agents. Bortezomib, thalidomide and lenalidomide were admin-
istered for refractory ⁄ relapse MM cases between December
2006 and September 2011; therefore, improvement in the OS
of Japanese patients with MM during the novel agent era is
probably due to the salvage therapy for insufficient response to
pre-ASCT induction or relapse cases.
The findings in this article should be confirmed in prospec-
tive studies.
Acknowledgments
The authors would like to thank to Dr Eiichi Nagura of Chutoen Gen-
eral Medical Center, Kakegawa, Shizuoka, Japan for providing us with
the OS data for Japanese patients with MM according to the ISS stage,
and to Dr Kosei Matsue of Kameda Medical Center, Kamogawa, Japan
and Dr Shinji Nakao of Kanazawa University, Kanazawa, Japan for the
critical reading of the manuscript.
Disclosure Statement
The authors declare no conflicts of interest except that Drs Hiroyuki
Takamatsu and Kazutaka Sunami have received honoraria fees from
Celgene Corporation.
References
1 Greipp PR, San Miguel J, Durie BG et al. International staging system for
multiple myeloma. J Clin Oncol 2005; 23: 3412–20.
2 Blade J, Samson D, Reece D et al. Criteria for evaluating disease response
and progression in patients with multiple myeloma treated by high-dose ther-
apy and haemopoietic stem cell transplantation. Myeloma Subcommittee of
the EBMT. European Group for Blood and Marrow Transplant. Br J Haema-
tol 1998; 102: 1115–23.
3 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’
for medical statistics. Bone Marrow Transplant 2013; 48: 452–8.
4 Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple
myeloma and the impact of novel therapies. Blood 2008; 111: 2516–20.
5 Venner CP, Connors JM, Sutherland HJ et al. Novel agents improve survival
of transplant patients with multiple myeloma including those with high-risk
disease defined by early relapse (<12 months). Leuk Lymphoma 2011; 52:
34–41.
6 Kastritis E, Zervas K, Symeonidis A et al. Improved survival of patients
with multiple myeloma after the introduction of novel agents and the appli-
cability of the International Staging System (ISS): an analysis of the Greek
Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152–7.
7 Costa LJ, Zhang MJ, Zhong X et al. Trends in utilization and outcomes of
autologous transplantation as early therapy for multiple myeloma. Biol Blood
Marrow Transplant 2013; 19: 1615–24.
8 Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Pat-
terns of survival in multiple myeloma: a population-based study of patients
diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25: 1993–9.
9 Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D. Risk of multi-
ple myeloma following medication use and medical conditions: a case–con-
trol study in Connecticut women. Cancer Epidemiol Biomarkers Prev 2006;
15: 2342–7.
10 Wang LH, Yang XY, Mihalic K, Xiao W, Li D, Farrar WL. Activation of
estrogen receptor blocks interleukin-6-inducible cell growth of human multi-
ple myeloma involving molecular cross-talk between estrogen receptor and
STAT3 mediated by co-regulator PIAS3. J Biol Chem 2001; 276: 31839–44.
11 Nagura E, Abe M, Iida S et al. Tahatsuseikotsuzuishu No Shinryoshishin,
3rd edn. Tokyo: Bunkodo, 2012.
12 Kim H, Sohn HJ, Kim S et al. New staging systems can predict prognosis of
multiple myeloma patients undergoing autologous peripheral blood stem cell
transplantation as first-line therapy. Biol Blood Marrow Transplant 2006; 12:
837–44.
13 Hari PN, Zhang MJ, Roy V et al. Is the International Staging System supe-
rior to the Durie-Salmon staging system? A comparison in multiple myeloma
patients undergoing autologous transplant. Leukemia 2009; 23: 1528–34.
14 Tan D, Ong KH, Koh LP et al. The impact of frontline risk-adapted strategy
on the overall survival of patients with newly diagnosed multiple myeloma:
an analysis of the Singapore multiple myeloma study group. Eur J Haematol
2012; 89: 136–44.
15 Iriuchishima H, Saitoh T, Handa H et al. A new staging system to predict
prognosis of patients with multiple myeloma in an era of novel therapeutic
agents. Eur J Haematol 2014; doi:10.1111/ejh.12407.
16 Tanaka H, Kosugi S, Kida T et al. Retrospective analysis of the recent treat-
ment strategies for the patients with myeloma-related diseases registered in
Kansai Myeloma Forum. Blood 2013; 122: (abstract #3385).
Cancer Sci | February 2015 | vol. 106 | no. 2 | 185 © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
Original Article
www.wileyonlinelibrary.com/journal/cas Takamatsu et al.
